Carnegie Mellon University’s NeuBase Therapeutics, Inc. Common Stock NBSE Stock Holding History

Carnegie Mellon University’s Portfolio NBSE Stock Details NBSE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-46,970	Closed	-$21.1K	–	6
2024 Q1	$21.1K	Hold	46,970	–	–	0.03%	5
2023 Q4	$34.8K	Hold	46,970	–	–	0.04%	4
2023 Q3	$40.9K	Hold	46,970	–	–	0.05%	5
2023 Q2	$87.8K	Sell	46,970 -1	-0%	-$3	0.12%	4
2023 Q1	$174K	Hold	46,971	–	–	0.12%	3
2022 Q4	$179K	Hold	46,971	–	–	0.1%	4
2022 Q3	$371K	Hold	46,971	–	–	0.21%	3
2022 Q2	$986K	Hold	46,971	–	–	0.5%	3
2022 Q1	$1.77M	Hold	46,971	–	–	0.74%	3
2021 Q4	$2.64M	Buy	+46,971	New	+$3.15M	1.06%	3

Other funds holding NBSE

BBA

Baader Bank Aktiengesellschaft Unterschleissheim, Germany $1.33B AUM 47.35% 1-Year Est. Return

Carnegie Mellon University's NBSE Position: Q2 2024 in Review

Carnegie Mellon University sold out of NeuBase Therapeutics, Inc. Common Stock (NBSE) in Q2 2024, closing a stake of 46,970 shares — an estimated $21.1K sold.

Carnegie Mellon University first reported a position in NBSE in Q4 2021 and held it in 10 quarters. The position peaked at $2.64M in Q4 2021. 3 funds tracked by Wall St. Rank hold NBSE as of Q2 2024.

Carnegie Mellon University reported no remaining NeuBase Therapeutics, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
Carnegie Mellon University sold 46,970 NeuBase Therapeutics, Inc. Common Stock shares in Q2 2024, an estimated $21.1K.
Carnegie Mellon University first reported a position in NeuBase Therapeutics, Inc. Common Stock in Q4 2021 and held it in 10 quarters.
Carnegie Mellon University's NeuBase Therapeutics, Inc. Common Stock position peaked at $2.64M in Q4 2021.
3 funds tracked by Wall St. Rank held NeuBase Therapeutics, Inc. Common Stock as of Q2 2024.

Based on Carnegie Mellon University's 13F filing for Q2 2024, filed 8 Aug 2024.